论文部分内容阅读
目的:观察小剂量HAG[高三尖杉酯碱(HHT)、阿糖胞苷(A ra-C)、G-CSF]预激方案对难治性急性髓系白血病(AM L)的近期临床疗效。方法:选择16例难治性AM L(原发难治性AM L 13例,骨髓增生异常综合征(M DS)转AM L 2例,慢性粒细胞白血病转AM L 1例。应用小剂量HAG方案治疗,其中14例治疗2个疗程,其余2例治疗1个疗程。结果:8例达完全缓解(CR),3例达部分缓解(PR),5例未缓解(NR),CR率为50%(8/16),总有效率68.8%(11/16)。结论:小剂量HAG预激方案是治疗难治性或复发性AM L患者的有效治疗方案。
OBJECTIVE: To observe the short-term clinical efficacy of low-dose HAG [HHT], Ara-C, G-CSF] pre-shock regimen in patients with refractory acute myeloid leukemia . Methods: 16 cases of refractory AM L (primary refractory AM L 13 cases, myelodysplastic syndrome (M DS) transferred AM 2 cases and chronic myeloid leukemia AM 1 cases) were selected.A small dose of HAG (CR), partial remission (PR) in 3, and unresponsiveness (NR) in 5, the CR rate was 50% (8/16), total effective rate 68.8% (11/16) .Conclusion: The low-dose HAG pre-shock regimen is an effective treatment for patients with refractory or recurrent AML.